PreDIVA Trial Falls Short
Dementia incidence in intervention group was no different from control, though targeting hypertension may protect, researchers say.
6401 RESULTS
Sort By:
Dementia incidence in intervention group was no different from control, though targeting hypertension may protect, researchers say.
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.
At AAIC, updated imaging data in autosomal-dominant AD shows that longitudinal MRI in large numbers of people confirms atrophy patterns. Tau PET is more variable in DIAN participants than in the Colombian families.
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
As data pours in, DIAN leaders strive to share and publish it without accidentally disclosing mutation status. The more is learned about preclinical AD, the harder this may get.
Sequencing the protein-coding DNA regions of more than 60,000 people sheds light on disease-causing mutations.
Researchers at AAIC presented congruent data on the place tau tangles take in AD progression, and their close correlation with cognitive decline.
While the relationship between Alzheimer’s and cardiovascular problems such as hypertension and diabetes remains complicated, a history of stroke is said to double the risk of late-onset AD.
Researchers at AAIC proposed several different measures of brain connectivity that may predict progression to AD.
Even as a slew of confounding variables blur results, studies still converge on the benefit of a cognitively stimulating life in old age.
Edited by Michael Wolfe and authored by leaders in the AD field, a new book challenges investigators to make real progress.
Different genetic factors underlie amyloid accumulation and atrophy, researchers at AAIC reported.
Increasingly, people must learn of their amyloid status and/or ApoE genotype in order to enter secondary prevention trials. At AAIC, researchers laid out their procedures to ethically break the news.
Read our full coverage of this year’s AAIC conference.